ISPOR Award for Excellence in Methodology in Pharmacoeconomics and Health Outcomes Research

Gerardo Machnicki

Research Excellence Awards Chair - Methodology in Pharmacoeconomics and Health Outcomes Research
Gerardo Machnicki, PhD, MSc, Director, Real World Evidence LATAM, Buenos Aires, Argentina

Methodology in Pharmacoeconomics and Health Outcomes Research Award Policies and Procedures

Description: The ISPOR Award for Excellence in Methodology in Pharmacoeconomics and Health Outcomes Research was established in 1997 to recognize outstanding research in the field of pharmacoeconomics and outcomes research methodology.

Criteria: This award is given to a distinguished paper that advances the field of outcomes research and is expected to have a substantial impact on the field with anticipated wide acceptance and application by others. The recipient is selected by the ISPOR Excellence Awards Committee from nominated publications that have appeared in print or e-pub in peer-review journals during the preceding calendar year (e-pub must be listed in Medline) and other communication venues (e.g. books, reports). Self-nominations are encouraged and accepted for consideration.

Selection Process: A call for nominations is placed in November-December Value & Outcomes Spotlight for articles published during the past twelve months to be considered for the ISPOR Award for Excellence in Methodology in Pharmacoeconomics and Health Outcomes Research. In addition, each Research Excellence Awards Committee member selects relevant publications in respected peer-reviewed journals during the preceding twelve months to be considered by the Excellence Awards Committee in the selection process. The Excellence Awards Committee meets via teleconference in February to discuss each of the nominated publications. They select the best demonstration of scientific excellence for that time period. The nominee is then forwarded to the Board of Directors for final approval. The corresponding author on the publication is given the award.

Nature of Award: The Award, presented at the ISPOR Annual International Meeting to the corresponding author of the paper, consists of a plaque, complimentary Annual International Meeting registration, roundtrip air fare, hotel, meal and miscellaneous expenses for two days, based upon current ISPOR travel policies. 

Nominations for the ISPOR Award for Excellence in Methodology in Pharmacoeconomics and Health Outcomes Research should be accompanied by an electronic version of the nominated paper and a letter of support that illustrates the positive attributes of the paper, and sent to Only ISPOR members may submit nominations (either their own publications or others).

Receipients of The ISPOR Award For Excellence in Methodology in Pharmacoeconomics and Health Outcomes Research

Claire Rothery, PhD Claire Rothery, PhD
Senior Research Fellow at the Centre for Health Economics (CHE), University of York, UK

For the paper, "A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage Decisions" Value In Health, 2016;19: 885-891

Claire Rothery, PhD, is a senior research fellow at the Centre for Health Economics (CHE), University of York, UK. She joined CHE in 2006 after completing her MSc in Health Economics at York. She holds a MSci in Mathematics, a PhD in Theoretical Physics, and an MPhil in Medical Statistics, all awarded by Queen’s University Belfast, Northern Ireland. Claire’s research interests focus on the development and application of decision analytic modelling methods and Bayesian approaches to Health Technology Assessment. She has specific interests in the use of constrained optimization methods in economic evaluation, and value of information analysis for informing research prioritization decisions. She is currently co-chairing the ISPOR Task Force on Emerging Good Practices for Value of Information analysis. Claire has led an extensive number of health technology appraisals for the National Institute for Health and Care Excellence (NICE) in the UK. She also served on the NICE Technology Appraisal Committee from 2013 to 2016, and is currently a member of the NICE Decision Support Unit. Claire serves as a co-editor for ISPOR’s scientific journal, Value in Health.

Anirban Basu, PhD Anirban Basu
Stergachis Family Endowed Professor and Director of the Pharmaceutical Outcomes Research and Policy Program at the University of Washington

For the paper, "A Framework for Prioritizing Research Investments in Precision Medicine,” Med Decis Making 2016;36:567–80.

Dr. Basu is a Stergachis Family Endowed Professor and Director of the Pharmaceutical Outcomes Research and Policy Program at the University of Washington, with additional appointments in the Department of Health Services, the Department of Economics, and the National Bureau of Economic Research. Anirban’s work sits at the intersection of microeconomics, statistics, and health policy. His research focuses on comparative and cost effectiveness analyses, causal inference methods, program evaluation, and outcomes research. Anirban is as an Associate Editor for Health Economics and Observational Studies. He is one of the panelists updating the Gold et al. book, Cost-Effectiveness in Health and Medicine. He is a past recipient of the ISPOR Bernie O’Brien New Investigator Award.

Anirban has a Bachelor’s degree from India, a Masters in Biostatistics from the University of North Carolina, Chapel Hill, and a PhD in Public Policy with a concentration in health economics from the University of Chicago.

Lisa A. Prosser, PhD

Lisa A. Prosser, PhD
Associate Professor and Interim Director, Child Health Evaluation and Research (CHEAR) Unit, University of Michigan, Ann Arbor, Michigan, USA

For the paper, "Measuring Family HRQoL Spillover Effects Using Direct Health Utility Assessment" Med Decis Making 2015;35:81–93.

Dr. Prosser is an Associate Professor and Interim Director of the Child Health Evaluation and Research (CHEAR) Unit at the University of Michigan. Her research focuses on measuring the comparative effectiveness and cost-effectiveness of childhood health interventions using methods of decision sciences and economics. Current research topics include: evaluating long-term health and economic outcomes for newborn screening programs using simulation modeling, measuring public values for screening programs, and developing new methods for valuing family spillover effects of childhood illness. Dr. Prosser's research on the economic impact of influenza vaccination and using decision modeling to project health outcomes for newborn screening has been used in setting national policy recommendations. Dr. Prosser received her PhD in health policy from Harvard University. She also holds a MS degree from the MIT Sloan School of Management and a MS from the Technology and Policy Program at MIT. Her undergraduate degree is in mathematics from Cornell University.

Ping Wang, PhD

Richard Norman, PhD
Senior Research Fellow at the Centre for Health Economics Research and Evaluation (CHERE), at the University of Technology, Sydney, Australia

For the paper, Efficiency and Equity: A Stated Preference Approach” Health Econ. 22: 568–581 (2013).

Richard Norman, PhD, is a Senior Research Fellow at the Centre for Health Economics Research and Evaluation (CHERE), at the University of Technology, Sydney. He joined CHERE in 2006, and holds a PhD from UTS in addition to an MSc in Health Economics, and a BA(Hons) in Philosophy and Economics, both from the University of York. He currently holds an Australian National Health and Medical Research Council (NHMRC) Early Career Researcher Fellowship, in addition to project funding from the NHMRC and Australian Research Council (ARC). His interests are in the fields of economic evaluation, discrete choice experiments, and health-related quality of life. He is a co-author on a range of methodological and applied studies in each of these areas, combining all three to answer questions relating to valuing health profiles for use in economic evaluation. Prior to working at UTS, he worked at Queen Mary, University of London developing economic analyses as part of NICE clinical guidelines.

Ping Wang, PhD

Ping Wang, PhD
Senior Biostatistician, Global Medical Affairs, Biogen Idec, Weston, MA, USA

For the paper, “Joint modeling of longitudinal outcomes and survival using latent growth modeling approach in a mesothelioma trial” Health Serv Outcomes Res Methodol 2012 June;12:182–99.

Ping Wang, PhD, a senior biostatistician, joined Global Medical Affairs team at Biogen Idec in February 2013. Before that, she was a project statistician at Eli Lilly and Company, supporting Global Health Outcomes. She is interested in developing and applying statistical methods in the area of health economics and outcomes research, such as joint modeling of longitudinal and survival data. She has worked on patient-reported outcome (PRO)-related projects across multiple therapeutic areas, including oncology, autoimmune, and diabetes. In addition, she worked on observational studies using large health care claims data to provide information on cost, resource utilization, adherence, etc. Ping obtained her PhD degree in statistics at the University of Wisconsin-Madison in 2009. During her graduate studies, her research was focused on the development and application of statistical methods for high-throughput genomics studies, such as microarrays and expression quantitative trait loci (eQTL) mapping studies.
Susan C. Griffin, PhD

Susan C. Griffin, PhD
Centre for Health Economics, University of York, Heslington, York, UK

For the paper, “Dangerous Omissions: The Consequences Of Ignoring Decision Uncertainty” Health Econ 2011;20:212–24.

Susan C. Griffin, PhD, is a Senior Research Fellow based in the Team for Economic Evaluation and Health Technology Assessment. She joined the Centre for Health Economics in 2002 and holds a BSc in Economics, an MSc in Health Economics and a PhD on ‘Dealing with uncertainty in the economic evaluation of health care technologies.’  In 2008, Dr. Griffin became a Research Council UK Academic Fellow in Health Economics and Public Health.  She also helped to develop a short course on the use of regression analysis for health economic evaluation.  Dr. Griffin currently serves as a member of the National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Committee. Dr. Griffin has contributed to numerous technology appraisals for NICE in her role as a member of one of the independent academic groups contracted to conduct assessments and evidence reviews for NICE.  In addition, Dr. Griffin has worked on economic evaluations in the fields of cardiovascular disease, HIV/AIDS, cancer and mental health.  Her research interests include the use of decision-analytic models in cost-effectiveness analysis and the use of evidence synthesis techniques and value of information analysis.  Dr. Griffin is currently researching the application of methods for economic evaluation in the field of public health.
Martin Hoyle, PhD

Martin Hoyle, PhD
PhD, Senior Research Fellow, Peninsula College of Medicine & Dentistry (PCMD), Universities of Exeter and Plymouth, Exeter, UK

For the paper, Hoyle M, Anderson R. Whose costs and benefits? Why Economic Evaluations Should Simulate Both Prevalent and All Future Incident Patient Cohorts. Med Decis Making 2010;30:426-37.

Martin Hoyle is a Senior Research Fellow at the Peninsula College of Medicine & Dentistry (PCMD), Universities of Exeter and Plymouth, UK.  In 2006, Martin joined the Peninsula Technology Assessment Group (PenTAG), part of PCMD, which performs health technology assessments for NICE in the UK.  Martin is a health economist and modeller, and is particularly interested in the application of mathematics and statistics to health technology assessment.  His methodological interests include: modelling costs and benefits for patients over the expected lifetime of the technology, future changes in drug prices, and application of survival analysis.  Martin has evaluated health technologies in several clinical areas including various cancers, multiple sclerosis and Alzheimer’s disease.  Martin has a degree in mathematics and a diploma in statistics, both from the University of Cambridge, UK, and gained a PhD in mathematical biology at the University of Nottingham (2000-2003).  He then worked at the University of Exeter as a post-doctoral researcher from 2004 to 2006, where he published mathematical models of cross-pollination in genetically modified crops.
Mara Airoldi BSc, MSc
Mara Airoldi BSc, MSc
Research Officer, Department of Management, London School of Economics and Political Science, London, UK

Airoldi M, Morton A. Adjusting Life for Quality Or Disability: Stylistic Difference Or Substantial Dispute? Health Econ 2009;18:1237–47.

Mara Airoldi is a Research Officer and PhD candidate in the Department of Management at the London School of Economics. She has a degree in Economics from Bocconi University in Milan where she specialized in Economics of Public Choice and an MSc in Decision Science from the LSE. Her research interests include both methodological and application issues in the area of resource allocation, with a focus on health care policies. Her methodological interests revolve around the normative foundation of resource allocation, which in the case of health care include the definition of objectives such as maximizing the health of a definite population and reducing health inequalities. Mara is particularly interested in bridging the gap between normative approaches and practice. To bridge this gap, her applied work aims at developing decision-analytic tools which employ normative principles, build on evidence and can be used in practice. In particular, she is currently collaborating with local agencies of the British National Health Service (Primary Care Trusts) to support their strategic purchasing process.
Mandy Ryan PhD
Mandy Ryan PhD
Professor in Health Economics & Director of the Valuation and Implementation Programme Health Economics Research Unit
Institute of Applied Health Sciences, University of Aberdeen Foresterhill, Aberdeen, UK

Ryan M, Watson V, Entwistle V. Rationalising the ‘irrational’: A think aloud study of discrete choice experiment responses. Health Economics 2009;18:321-36.

Professor Ryan joined HERU in 1987 after graduating from the University of Leicester in 1986 with a BA (Hons) in Economics and from the University of York with an MSc in Health Economics. In 1995 she graduated from the University of Aberdeen with a PhD in Economics concerned with the application of contingent valuation and discrete choice experiments in health economics. In 1997 Mandy was awarded a 5-year MRC Senior Fellowship to develop and apply discrete choice experiments in health care, in 2002 she was awarded a Personal Chair in Health Economics by the University of Aberdeen and in 2006 she was elected as a Fellow of the Royal Society of Edinburgh. She was a member of the RAE 2008 sub-panel 7 (Health Services Research). Professor Ryan currently directs the Preference Elicitation Theme within the Preference and Elicitation and Assessment of Technologies (PEAT) programme of work within HERU. She has worked with academics, government and the pharmaceutical industry and has published widely in the field of health economics generally, and monetary valuation more specifically. Professor Ryan also has extensive teaching experience, and is currently Director of HERU's Distance Learning Course.
Andrea Manca, MSc, PhD
Andrea Manca, MSc, PhD
Centre for Health Economics (CHE)
The University of York, UK

Manca A, Lambert PC, Sculpher MJ, Rice N (2007) Cost-effectiveness analysis using data from multinational trials: the use of bivariate hierarchical modelling, Med Decision Making 2007;27:471-90.

Andrea Manca (MSc Health Economics and PhD Economics; York, UK) is Senior Research Fellow in the Team for Economic Evaluation and Health Technology Assessment - led by Professor Mark Sculpher – part of the Centre for Health Economics at the University of York (UK). His research interests include the application of statistical methods for the analysis of cost effectiveness and health outcomes data, as well as the use of evidence synthesis techniques for health care decision making. In 2007 Andrea completed a post doctoral Research and Training Fellowship in Health Services Research awarded by The Wellcome Trust, to investigate the use of statistical methods for the analysis of multicentre and multinational individual patient level cost effectiveness data with the objective to inform reimbursement decisions in different jurisdictions. As part of his Fellowship, Andrea spent a six month visiting period at the Institute for Clinical Evaluative Sciences in Toronto (Canada). Andrea has evaluated health technologies in several clinical areas including breast and advanced colorectal cancer, endovascular aneurysm repair, coronary revascularisation, diabetes, neck and chronic low back pain, surgical interventions for urinary stress incontinence, and hysterectomy. Andrea is a member of the faculty of the York Expert Workshops in the Socio Economic Evaluation of Medicines and serves as co-editor of the scientific journal Value in Health.
Anirban Basu
Anirban Basu PhD
Associate Professor, Dept. of Health Services
School of Public Health, University of Washington, Seattle, USA

Basu A, Arondekarc BV, Rathouz PJ. Scale of interest versus scale of estimation: comparing alternative estimators for the incremental costs of a comorbidity. Health Econ 2006;15:1091–107.

Anirban Basu (MS, Biostatistics UNC- Chapel Hill, and PhD Public Policy University of Chicago) is an Assistant Professor of Medicine at the University of Chicago. Anirban’s research interests are in cost-effectiveness analyses (CEA) of medical interventions, decision analysis methodology, health econometrics and applied health services research. He has extensive experience in modeling health expenditure data. He has also worked on the theoretical and empirical foundations in cost-effectiveness analyses and value of information analyses in the context of prostate cancer and schizophrenia. He has authored or co-authored several journal articles and book chapters on these and other topics. Some of his publications have appeared in the Journal of Health Economics, Health Economics, Biostatistics, Statistics in Medicine, Medical Decision Making and Schizophrenia Research. Anirban is also working on identifying and measuring spillover effects of patient’s health to their family members and incorporating these effects in CEA. His other work include exploring the use of instrumental variables in the presence if heterogeneity and self-selection behavior, estimating future value of research in diagnosing and finding a cure for Duchenne muscular dystrophy and developing comprehensive simulation models for evaluating cost-effectiveness of pharmacological treatment algorithms in schizophrenia.
Maiwenn Al, PhD
Maiwenn Al, PhD
Institute for Medical Technology Assessment
Erasmus MC – University Medical Center Rotterdam

Oostenbrink, JB and Al, MJ. The analysis of incomplete cost data due to dropout. Health Econ 14:763-76; 2005

Maiwenn Al obtained her Master degree in Mathematics at Leiden University in 1991. Since 1992 she has been working at the institute for Medical Technology Assessment (iMTA) at Erasmus University Rotterdam. From 1996 to 1999 she held a Pfizer Health Economics Fellowship and in 2001 she obtained her PhD degree at the Erasmus University Rotterdam. Her research focuses on modelling studies and methods for dealing with uncertainty in economic evaluations. Together with Ben van Hout, Maiwenn developed the cost-effectiveness acceptability curve, now widely used as a method to describe uncertainty around ICERs. Her most current research focuses on methods for censored data, including applications in the area of mental health care, and budget allocation models. The latter topic involves both theoretical models and a survey into the decision makers’ view on health care objectives and budget constraints.
Joshua A Salomon, PhD
Joshua A Salomon, PhD
Assistant Professor of International Health
Harvard School of Public Health.
His research focuses on measurement of population health status and health valuations in community surveys; modeling and forecasting of health outcomes and disease burden; and evaluation of the potential impact and cost-effectiveness of health interventions. A major emphasis has been on development of new approaches to data collection and analysis of health measurements, with a particular focus on developing country settings and aging populations. Another major research area revolves around development of analytic tools for priority-setting in global health. The goal of this work is to combine techniques of simulation modeling with decision analysis to inform policies regarding the use of existing health interventions and priorities for development of new technologies. Salomon earned a BA from Harvard College and a PhD in Health Policy and Decision Sciences from Harvard University.
Andrew H Briggs, BA, MSc, D.Phil
Andrew H Briggs, BA, MSc, D.Phil.
Health Economics Research Centre (HERC)
Department of Public Health, University of Oxford

Briggs AH, Clark T, Wolstenholme J, Clark P. Missing…presumed at random; costanalysis of incomplete data. Health Econ 2003; 12:337-92.

An economist by training, Andrew took an interest in health economics as an undergraduate and then took the York Masters programme in Health Economics. Following a DPhil in Health Economics at the University of Oxford (Nuffield College) he was awarded a Training Fellowship from the UK MRC to work on statistical issues in cost-effectiveness analysis and successfully completed an MSc Applied Statistics. Also as part of the award, he spent a sabbatical visit at the Centre for Evaluation of Medicines (CEM) at McMaster University working with Professors Bernie O’Brien and Andy Willan, and he remains a research associate at CEM. A member of Oxford’s Health Economics Research Centre (under the directorship of Professor Alastair Gray) since 1996, Andrew currently holds a Public Health Career Scientist Award from the UK Department of Health.

Andrew’s research interests include both methodological issues in cost-effectiveness analysis and applications. His methodological interests revolve principally around statistical issues for economic appraisals conducted alongside clinical trials and the use of decision models for evaluating health care interventions. Applications include the cost-effectiveness of interventions in cardiovascular disease and diabetes, as well as the use of alternative prostheses for total hip replacement and pharmaceutical treatment for respiratory disease.

He has acted as adviser to NICE in relation to its guidance to manufacturers, he serves on the UK Health Technology Assessment Commissioning Board, and he as acted as consultant to the World Bank. He is on the editorial board of Medical Decision Making and is a co-editor of Value in Health.
Jeffrey S. Hoch PhD
Jeffrey S. Hoch PhD
Assistant Professor of Health Economics, Department of Epidemiology and Biostatistics
The University of Western Ontario, London, Ontario, Canada

“Something Old, Something New, Something Borrowed, Something BLUE: A Framework for the Marriage of Health Econometrics and Cost-effectiveness Analysis.” Health Economics 2002; 11: 415-430.

Jeffrey S. Hoch received his PhD in health economics from the Johns Hopkins Bloomberg School of Public Health. He also holds a Masters in Economics from the Johns Hopkins University and a Bachelor of Arts degree in Quantitative Economics and Decision Sciences from the University of California at San Diego. Dr. Hoch is currently an Assistant Professor with a primary appointment in the Department of Epidemiology and Biostatistics and cross appointments in the Department of Family Medicine and the Department of Psychiatry at the University of Western Ontario (UWO). Dr. Hoch has taught Health Economics and Economic Evaluation classes in Canada, Europe and the United States. Since 1998, Dr. Hoch has delivered over 65 presentations at scientific conferences. In 2003, he was awarded a Faculty Development Mini Fellowship from the Faculty of Medicine and Dentistry at UWO to develop a case-based medical economics curriculum. Dr. Hoch has held research grants from a number of government and industry sponsors including the Canadian Institutes for Health Research (CIHR), the Natural Sciences and Engineering Research Council (NSERC) and the Canadian Institute for Health Information (CIHI). In addition, Dr. Hoch has received peer-reviewed career funding in the form of a Career Scientist Award from the Ontario Ministry of Health and Long Term Care. Currently, Dr. Hoch is pursuing research on economic evaluation and statistical methodology as well as applied health economics. Special interests include mental health and home care. Dr. Hoch’s work has appeared in journals such as Archives of General Psychiatry, The British Journal of Psychiatry, and Health Economics.
Bernie O'Brien, BA, MSc, PhD
Bernie O'Brien, BA, MSc, PhD
Research Officer, Department of Management, London School of Economics and Political Science, London, UK

O’Brien BJ, Gasten K, Willlan AR, Falukner LA. Is there a link in consumers’ threshold value for cost-effectiveness in health care? Health Econ 2002;11:174-80.

A health economist by profession, Bernie O’Brien received his Bachelors and Masters degrees in Economics from the University of York (UK) and his PhD (Economics) from Brunel University in London (UK) before moving to Canada in 1990. He is currently a Professor in the Department of Clinical Epidemiology and Biostatistics at McMaster University, Co-Director of the Centre for Evaluation of Medicines at St. Joseph’s Hospital and an Associate of the Centre for Health Economics and Policy Analysis at McMaster. In 2001-2002 he was a Visiting Professor at the University of Sydney, Australia.

His main research interests are (1) methods of economic evaluation as applied to new therapeutic interventions, particularly in the context of clinical trials; (2) decision analysis and allied mathematical modeling; (3) cost-benefit analysis and monetary valuation techniques; and (4) pharmaceutical policy analysis. Peer-reviewed career funding awards include a PMAC/Medical Research Council of Canada Investigator Award in Health Sciences (1995-2000) and a Senior Investigator Award from the Canadian Institutes of Health Research (2002-2007). Other awards for his research include the 1995 Society for Medical Decision Making prize for ‘Outstanding Paper by a Young Investigator’; the 1997 Piafsky Young Investigator Award from the Canadian Society for Clinical Pharmacology and the Wilfred Bigelow Traveling Fellowship (2002) from the North American Society for Pacing and Electrophysiology (NASPE).

He has held research grants from a number of government and industry sponsors including the Canadian Institutes for Health Research (CIHR) and the Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Publications include the widely cited textbook on economic evaluation with Drummond, Stoddart and Torrance and over 100 peer-reviewed journal papers. He is currently on the editorial boards of Health Economics, Pharmacoeconomics, Clinical Therapeutics, and is an Associate Editor of Medical Decision Making. In 2001 he was appointed to the National Blood Safety Council.
Richard Miller
Richard D. Miller PhD

Miller RD, French HE III. Is there a link between pharmaceutical consumption and improved health in OECD countries? Pharmacoeconomics 2000;18 (Suppl.1):S33-45.

Andrew R. Willan
Andrew R. Willan PhD

Willan AR, O’Brien BO. Sample size and power issues in estimating incremental cost-effectiveness rations from clinical trials and data. Health Econ 1999:8:203-11.

Joel W. Hay
Joel W. Hay PhD
Editor-in-Chief, Value in Health – The Journal of the International Society for Pharmacoeconomics and Outcomes Research.
Gerry Oster
Gerry Oster PhD

Cheville A, Chen A, Oster G, et al. A Randomized Trial to Assess Effectiveness and Costs in Clinical Practice. Arch Intern Med 1996;156:731-9.

Daniel B. Mark
Daniel B. Mark MD, MPH

Mark DB, Hlatky MH, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-24.

Return to Awards Main Page